Stock Analiz

IDEAYA Biosciences, Inc. (IDYA) financials: revenue, earnings and cash flow

Fiscal 2017–2025 + TTM · from SEC filings · data as of November 13, 2026

Summary

Net income in fiscal 2025 was -$114M, a net margin of -52.0%; the best year in this period was 2017 with -$12M.

Over the twelve months to September 30, 2026, revenue was $37M and net income -$420M.

Free cash flow was -$73M in fiscal 2025 and positive in 1 of the 9 years shown.

The diluted share count rose 12625% over the period (dilution).

Revenue, profit and cash flow by year

Revenue
2019: $020192020: $20M20202021: $28M20212022: $51M20222023: $23M20232024: $7M20242025: $219M2025$219M
Net income
2017: -$12M172018: -$34M182019: -$42M192020: -$34M202021: -$50M212022: -$59M222023: -$113M232024: -$274M242025: -$114M25-$114M
Free cash flow
2017: -$14M172018: -$29M182019: -$41M192020: $55M202021: -$58M212022: -$91M222023: -$118M232024: -$251M242025: -$73M25-$73M
EPS (diluted)
2017: $-17.06172018: $-35.92182019: $-3.36192020: $-1.40202021: $-1.41212022: $-1.42222023: $-1.96232024: $-3.36242025: $-1.2825$-1.28

Income statement

Fiscal yearTTM202520242023202220212020201920182017
Revenue$37M$219M$7M$23M$51M$28M$20M$0——
Gross profit——————————
Operating income-$463M-$159M-$327M-$134M-$63M-$50M-$35M-$44M-$36M-$14M
Net income-$420M-$114M-$274M-$113M-$59M-$50M-$34M-$42M-$34M-$12M
EPS (diluted)$-4.49$-1.28$-3.36$-1.96$-1.42$-1.41$-1.40$-3.36$-35.92$-17.06
R&D$387M$315M$295M$130M$90M$58M$40M$34M$32M$12M
Revenue growth—+3024.4%−70.1%−54.1%+82.3%+43.0%————

Cash flow

Fiscal yearTTM202520242023202220212020201920182017
Operating cash flow-$347M-$71M-$248M-$115M-$87M-$56M$55M-$39M-$28M-$12M
Capital spending-$2M-$2M-$4M-$2M-$3M-$3M-$493000-$1M-$2M-$2M
Free cash flow-$350M-$73M-$251M-$118M-$91M-$58M$55M-$41M-$29M-$14M
Dividends paid—$0$0$0$0$0$0$0——
Buybacks——————————
Stock-based pay$61M$46M$35M$18M$12M$8M$4M$2M$950000$136000

Balance sheet

Fiscal yearTTM202520242023202220212020201920182017
Cash—$639M$676M$525M$365M$247M$284M$99M$90M$6M
Debt—$28M$19M$3M$3M$5M$7M$7M$8M—
Equity—$1.0B$1.1B$621M$349M$302M$198M$100M-$49M-$16M
Total assets—$1.1B$1.1B$649M$388M$381M$298M$113M$97M—
Shares (diluted)103M88M82M58M41M35M25M12M1M1M

Margins and returns

Fiscal yearTTM202520242023202220212020201920182017
Gross margin——————————
Operating margin-1267.4%-72.8%-4671.1%-574.9%-122.7%-179.9%-180.9%———
Net margin-1149.6%-52.0%-3921.1%-483.0%-115.2%-178.1%-176.6%———
FCF margin-957.4%-33.6%-3592.0%-502.9%-177.9%-209.1%281.3%———
ROIC—-12.0%-23.9%-17.0%-14.0%-13.0%-13.6%-32.6%——
ROE—-11.1%-25.9%-18.2%-16.8%-16.5%-17.4%-41.8%70.2%75.4%

Frequently asked questions

What is IDEAYA Biosciences’s annual revenue?

$219M in fiscal 2025 and $37M over the twelve months to September 30, 2026.

How much profit does IDEAYA Biosciences make?

Net income was -$114M in fiscal 2025 (net margin -52.0%).

Is IDEAYA Biosciences’s revenue growing?

Yes: revenue rose 3024.4% in fiscal 2025 compared with the year before.

From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.